COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1637: Articles 16361-16370  | Next

Study Pre-protocol for 'BronchStart - The Impact of the COVID-19 Pandemic on the Timing, Age and Severity of Respiratory Syncytial Virus (RSV) Emergency Presentations; a Multi-Centre Prospective Observational Cohort Study'
Williams, T. C., Lyttle, M. D., Cunningham, S., Sinha, I., Swann, O., Maxwell-Hodkinson, A., Roland, D., Paediatric Emergency Research in the UK and Ireland (PERUKI)
10.1101/2021.04.18.21255700 — Posted: 2021-04-20
Simulation of aerosol and droplet spread during upper airway and gastrointestinal endoscopy
Heymer, J., Dengler, F., Krohn, A., Jaki, C., Schilling, T., Mueller-Schilling, M., Kandulski, A., Ott, M.
10.1101/2021.04.20.21255743 — Posted: 2021-04-20
Emergence of the novel SARS-CoV-2 lineage P.4.1 and massive spread of P.2 in South Brazil
Sant'Anna, F. H., Varela, A. P. M., Prichula, J., Comerlato, J., Comerlato, C. B., Roglio, V. S., Pereira, G. F. M., Moreno, F., Seixas, A., Wendland, E. M.
10.1101/2021.04.14.21255429 — Posted: 2021-04-20
Inactivation of SARS-CoV-2 in chlorinated swimming pool water
Brown, J. C., Blackwell, A., Moshe, M., Barclay, W. S.
10.1101/2021.04.19.440446 — Posted: 2021-04-20
Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines
Barry, M. A., Mudrick, H., McGlinch, E., Parrett, B., Hemsath, J., Barry, M., Rubin, J., Uzendu, C., Hansen, M., Erskine, C., VanKeulen, V., Drelich, A., Tseng, C.-T. K., Massey, C. S., Fida, M., Suh, G. A., Peikert, T., Block, M., Olivier, G.
10.1101/2021.04.20.440651 — Posted: 2021-04-20
Drug repurposing to face Covid-19: Celastrol, a potential leading drug capable of inhibiting SARS-CoV-2 replication and induced inflammation
Fuzo, C. A., Martins, R. B., Fraga-Silva, T. F. C., Amstalden, M. K., Canassa-DeLeo, T., Souza, J. P., Lima, T. M., Faccioli, L. H., Franca, S. C., Bonato, V. L. D., Neto, E. A., Dias-Baruffi, M.
10.1101/2021.04.20.439992 — Posted: 2021-04-20
Ultrapotent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants
Li, T., Han, X., Gu, C., Guo, H., Zhang, H., Wang, Y., Hu, C., Wang, K., Liu, F., Luo, F., Zhang, Y., Hu, J., wang, W., Li, S., Hao, Y., Shen, M., Huang, J., Long, Y., Song, S., Wu, R., Mu, S., Chen, Q., Gao, F., Wang, J., Long, S., Li, L., Wu, Y., Gao, Y., Xu, W., Cai, X., Qu, D., Zhang, Z., Zhang, H., Li, N., Gao, Q., Zhang, g., He, C., Wang, W., Ji, X., Tang, N., Yuan, Z., Xie, Y., Zhang, B., Yang, H., Huang, A., Jin, A.
10.1101/2021.04.19.440481 — Posted: 2021-04-20
Sensitive on-site detection of SARS-CoV-2 by ID NOW COVID-19
Krause, E., Puyskens, A., Bourquain, D., Brinkmann, A., Biere, B., Schaade, L., MIchel, J., Nitsche, A.
10.1101/2021.04.18.21255688 — Posted: 2021-04-20
A Feasibility Trial to Evaluate the Composite Efficacy of Inhaled Nitric Oxide in the Treatment of Covid 19 Pneumonia : Impact on Viral Load and Clinical Outcomes
Moni, M., Madathil, T., Sathyapalan, D., Menon, V., Gutjahr, G., Edathadathil, F., Sureshkumar, D., Prasanna, P., Jose, S., Jerome, R., Krishnan, A., Pillai, I., Kumar, G., Nair, B., Jayant, A.
10.1101/2021.04.15.21255300 — Posted: 2021-04-20
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Rossignol, J.-F., Bardin, M. C., Oaks, J. B., Bostick, B. G., Vora, K. N., Fulgencio, J., Mogelnicki, D., Brechot, C.
10.1101/2021.04.19.21255441 — Posted: 2021-04-20

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).